Logo
x

Search

Subscribe Now

breast cancer

Samsung Bioepis’s Ontruzant (biosimilar, trastuzumab) Receives the Health Canada Approval for the Treatment of Breast & Gastric Cancer

Samsung Bioepis’s Ontruzant (biosimilar, trastuzumab) Receives the Health Canada Approval for the Treatment of Breast & Gastric Ca...

  • February 2, 2022
Eli Lilly's Verzenio (abemaciclib) Receives the US FDA's Approval for People with HR+ HER2- High Risk Early Breast Cancer

Eli Lilly's Verzenio (abemaciclib) Receives the US FDA's Approval for People with HR+ HER2- High Risk Early Breast Cancer

  • October 13, 2021
PharmaShots Interview: Q BioMed's Denis Corin Shares Insights on the Agreement to Serve US Department of Defense and Veterans Affairs

PharmaShots Interview: Q BioMed's Denis Corin Shares Insights on the Agreement to Serve US Department of Defense and Veterans Affa...

  • July 13, 2021
PharmaShots Interview: Daiichi Sankyo's Ken Keller Shares Insights on NICE Recommendation for Enhertu in HER2 Positive Breast Cancer

PharmaShots Interview: Daiichi Sankyo's Ken Keller Shares Insights on NICE Recommendation for Enhertu in HER2 Positive Breast Canc...

  • June 2, 2021
Zydus Cadila Launches Ujvira (biosimilar- trastuzumab emtansine) for Early and Advanced HER2 Positive Breast Cancer

Zydus Cadila Launches Ujvira (biosimilar- trastuzumab emtansine) for Early and Advanced HER2 Positive Breast Cancer

  • May 24, 2021
Boehringer Ingelheim to Acquires NBE-Therapeutics ~ $1.5B

Boehringer Ingelheim to Acquires NBE-Therapeutics ~ $1.5B

  • December 11, 2020
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.